WO2001080839A3 - Use of naphthindazole-4,9-quinones as antiparasitic agents - Google Patents

Use of naphthindazole-4,9-quinones as antiparasitic agents Download PDF

Info

Publication number
WO2001080839A3
WO2001080839A3 PCT/DE2001/000975 DE0100975W WO0180839A3 WO 2001080839 A3 WO2001080839 A3 WO 2001080839A3 DE 0100975 W DE0100975 W DE 0100975W WO 0180839 A3 WO0180839 A3 WO 0180839A3
Authority
WO
WIPO (PCT)
Prior art keywords
spp
naphthindazole
quinones
compounds
general formula
Prior art date
Application number
PCT/DE2001/000975
Other languages
German (de)
French (fr)
Other versions
WO2001080839A2 (en
Inventor
Oliver Kayser
Hartmut Laatsch
Albrecht Ferdinand Kiderlen
Original Assignee
Bundesrep Deutschland
Oliver Kayser
Hartmut Laatsch
Albrecht Ferdinand Kiderlen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bundesrep Deutschland, Oliver Kayser, Hartmut Laatsch, Albrecht Ferdinand Kiderlen filed Critical Bundesrep Deutschland
Priority to AU2001250279A priority Critical patent/AU2001250279A1/en
Publication of WO2001080839A2 publication Critical patent/WO2001080839A2/en
Publication of WO2001080839A3 publication Critical patent/WO2001080839A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to pharmaceutical compositions which are characterised in that they contain at least one of the compounds of general formula (I), to their pharmacologically suitable salts and to the use of compounds of general formula (I) or their pharmacologically suitable salts for prophylactic administration or for therapeutic treatment of a parasitic infection caused by Trypanosoma spp., Leishmania spp., Plasmodium spp., Cryptosporidium parvum, Eimeria spp., Toxoplasma gondii or Pneumocystis spp.
PCT/DE2001/000975 2000-04-20 2001-03-09 Use of naphthindazole-4,9-quinones as antiparasitic agents WO2001080839A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001250279A AU2001250279A1 (en) 2000-04-20 2001-03-09 Use of naphthindazole-4,9-quinones as antiparasitic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10020812.6 2000-04-20
DE10020812A DE10020812C2 (en) 2000-04-20 2000-04-20 Use of naphthindazole-4,9-quinones as antiparasitic agents

Publications (2)

Publication Number Publication Date
WO2001080839A2 WO2001080839A2 (en) 2001-11-01
WO2001080839A3 true WO2001080839A3 (en) 2002-05-23

Family

ID=7640185

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2001/000975 WO2001080839A2 (en) 2000-04-20 2001-03-09 Use of naphthindazole-4,9-quinones as antiparasitic agents

Country Status (3)

Country Link
AU (1) AU2001250279A1 (en)
DE (1) DE10020812C2 (en)
WO (1) WO2001080839A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7887817B2 (en) 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
DE10203195A1 (en) * 2002-01-25 2003-08-07 Zentaris Ag Use of alkylphosphocholines in the preventive treatment of protozoal diseases
KR102511507B1 (en) * 2020-09-16 2023-03-17 경희대학교 산학협력단 Novel benzoindazoltrione derivatives and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2107053A1 (en) * 1970-02-17 1971-08-26 Shell Internationale Research Maat schappij N V , Den Haag (Niederlande) Substituted 1,4 quinone derivatives
DE3831332A1 (en) * 1988-09-15 1990-03-29 Basf Ag NAPHTHINDAZOL-4,9-CHINONE AND ITS USE IN DISABLING UNUSUAL PLANT GROWTH

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2107053A1 (en) * 1970-02-17 1971-08-26 Shell Internationale Research Maat schappij N V , Den Haag (Niederlande) Substituted 1,4 quinone derivatives
DE3831332A1 (en) * 1988-09-15 1990-03-29 Basf Ag NAPHTHINDAZOL-4,9-CHINONE AND ITS USE IN DISABLING UNUSUAL PLANT GROWTH

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. ZEECK ET AL.: "Isolierung und Konstitution der Isochromanchinon-Antibiotika beta- und gamma-Naphthocyclinon", LIEBIGS ANN. CHEM., no. 7, 1974, pages 1100 - 1025, XP001038515 *
B. KRONE, A. ZEECK: "13C-NMR and CD Spectroscopy with Isochromanquinones - Potent Methods To Determine the Stereochemistry and the Tautomeric Equilibrium in This Group of Antibiotics", LIEBIGS ANN. CHEM., no. 9, 1987, pages 751 - 758, XP001026139 *
H. LAATSCH: "Partialsynthese von Actinorhodin", LIEBIGS ANN. CHEM., no. 4, 1987, pages 297 - 304, XP001026119 *
S. DANOUN ET AL.: "Synthesis and protozoocidal activity of new 1,4-naphthoquinones", HETEROCYCL. COMMUN., vol. 5, no. 4, 1999, pages 343 - 348, XP001037195 *
V. K. TANDON ET AL.: "Synthesis and Pharmacoogical Studies of Some (1,4)-Naphthoquinon[3,2-c]-1H-pyrazoles, 2-Substituted Amino-1,4-nahthoquinones, and Related Compounds", ARCH. PHARM. (EINHEIM, GER.), vol. 323, no. 7, 1990, pages 383 - 385, XP001037273 *

Also Published As

Publication number Publication date
WO2001080839A2 (en) 2001-11-01
AU2001250279A1 (en) 2001-11-07
DE10020812A1 (en) 2001-10-31
DE10020812C2 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
GB0126151D0 (en) Administration of medicaments by vaporisation
EP1461044A4 (en) Pharmaceutical compositions comprising active vitamin d compounds
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
GC0000397A (en) Olopatadine formulations for topical administration
UA90518C2 (en) Pharmaceutical composition in the form of a tablet suitable for dissolution in the buccal cavity, comprising a narcotic active ingredient and amine
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
EP1337249A4 (en) Compositions and methods for administration of pharmacologically active compounds
HRP20040545A2 (en) Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
IL157933A (en) Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions comprising them
HUP0303891A3 (en) Pharmaceutically active piridine derivatives, process for their preparation and pharmaceutical compositions containing them
PL374325A1 (en) Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
SI1417206T1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
AU2002309038A1 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
WO2002067865A3 (en) N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
EP1509220A4 (en) A pharmaceutical composition for the treatment of seborrhea containing 4-hydroxy-5-methoxy-4- 2-methyl-3(3-methyl-2-butenyl)-2-oxiranyl -1-oxaspiro 2,5 octan-6-one
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
WO2001080839A3 (en) Use of naphthindazole-4,9-quinones as antiparasitic agents
HUP0102979A3 (en) Pharmaceutical compositions for treating gastro-esophageal reflux disease containing (+)-norcisapride as active ingredient
IL152533A0 (en) NOVEL FORMULATIONS OF alpha-2,4-DISULFOPHENYL-N-TERTBUTYLNITRONE
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
PL352528A1 (en) Novel xanthone compounds, their preparation and use as medicament
WO2000048447A3 (en) Composition for treatment of external secretion disorders except hypolacrimation
WO2001080838A3 (en) Use of n2-substituted benz[f]indazole-4,9-quinones as antiparasitic agents
HUP0401406A3 (en) Novel imidazolidine derivatives as vla-4 antagonists, their preparation their use and pharmaceutical compositions containing them
HUP0401912A3 (en) Pharmaceutically acceptable salts of 20(s)-camptothecins, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AU BA BB BG BR CA CN CR CU CZ DM DZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LS LT LV MA MG MK MN MX MZ NO NZ PL RO SG SI SK TT UA US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AU BA BB BG BR CA CN CR CU CZ DM DZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LS LT LV MA MG MK MN MX MZ NO NZ PL RO SG SI SK TT UA US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP